| ADRB2 |
|---|
| Full Name | Beta-2 Adrenergic Receptor |
| Gene Symbol | ADRB2 |
| Chromosomal Location | 5q31-q32 |
| NCBI Gene ID | 154 |
| OMIM ID | 109630 |
| Ensembl ID | ENSG00000169252 |
| UniProt ID | P07550 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Asthma, COPD, Heart Failure |
ADRB2 encodes the β2-adrenergic receptor (β2-AR), a G-protein coupled receptor that mediates the effects of epinephrine and norepinephrine. While sharing structural homology with β1-AR, β2-AR has distinct pharmacological properties, tissue distribution, and physiological functions. In the central nervous system, β2-AR plays crucial roles in memory consolidation, synaptic plasticity, and neuroprotection, making it highly relevant to neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
The β2-AR primarily couples to Gs proteins, stimulating adenylyl cyclase and increasing cAMP, similar to β1-AR. However, it can also couple to Gi/o proteins in certain cell types, allowing for more diverse signaling. Additionally, β2-AR exhibits unique properties including ligand-independent constitutive activity and the ability to signal through β-arrestin-biased pathways.
¶ Molecular Biology and Structure
The ADRB2 gene is located on chromosome 5q31-q32 and consists of 4 exons spanning approximately 1.8 kilobases. The single coding exon encodes a 413-amino acid protein. The gene promoter contains:
- TATA box: Core promoter element
- CRE elements: cAMP response elements for regulated expression
- AP-1 sites: Responsive to growth factors and cytokines
- GRE: Glucocorticoid response elements
- NF-κB elements: Allows inflammatory regulation
Multiple transcription start sites enable complex regulation of expression across tissues.
The β2-adrenergic receptor has classical GPCR architecture:
- N-terminal extracellular domain (1-39 aa): Contains two N-linked glycosylation sites
- Transmembrane domains (TM1-TM7): Seven α-helices forming the ligand-binding pocket
- Extracellular loops (ECL1-ECL3): ECL2 contains a conserved disulfide bond
- Intracellular loops (ICL1-ICL3): ICL3 is the primary G protein coupling domain
- C-terminal tail (342-413 aa): Contains serine/threonine phosphorylation sites
The ligand-binding pocket accommodates catecholamines with high affinity. Key structural features include:
- Asp113 in TM3 (counterion for catecholamine amine)
- Ser203, Ser204, Ser207 (hydrogen bond donors for catechol hydroxyls)
- Phe282 (hydrophobic interactions with aromatic ring)
Multiple splice variants of ADRB2 have been described:
- β2-AR1: Full-length 413 aa (predominant)
- β2-AR2: Alternative C-terminus
- Truncated variants: May have distinct signaling properties
Upon agonist binding:
- Conformational change activates Gs protein
- Gαs-GTP stimulates adenylyl cyclase
- cAMP production increases
- PKA activation leads to substrate phosphorylation
- Physiological effects on muscle relaxation, glycogenolysis, gene transcription
In some cell types, β2-AR couples to Gi/o:
- Inhibition of adenylyl cyclase reduces cAMP
- βγ subunits activate PI3K pathways
- Cell-type specificity determines coupling preference
β2-AR signals through β-arrestins independently of G proteins:
- ERK1/2 activation via β-arrestin scaffolds
- Akt activation through similar mechanisms
- Receptor internalization and recycling
- Biased signaling potential for drug design
β2-AR exhibits unique properties:
- Constitutive activity: Some basal signaling without agonist
- Inverse agonism: Some ligands reduce baseline activity
- Allosteric modulators: Bind at distinct sites
- Oligomerization: May form heteromers with other GPCRs
β2-AR plays a critical role in memory consolidation:
- Hippocampal LTP: β2-AR activation enhances long-term potentiation
- Memory enhancement: Agonists improve consolidation in multiple paradigms
- cAMP/PKA/CREB pathway: Required for consolidation effects
- Time window: Effects greatest during post-training period
The noradrenergic system from the locus coeruleus modulates memory through β2-AR, particularly for emotionally salient information.
β2-AR signaling affects APP processing and Aβ toxicity:
- APP processing: cAMP can influence α-secretase activity
- Aβ production: Effects are context-dependent
- Synaptic protection: β2-AR activation protects against Aβ-induced synaptic dysfunction
- Neuronal survival: Anti-apoptotic signaling through PI3K/Akt
β2-AR has potent anti-inflammatory effects in the brain:
- Microglial inhibition: β2-AR activation reduces pro-inflammatory cytokine release
- TNF-α suppression: Reduces microglial activation
- IL-1β and IL-6: Suppressed by β2-agonists
- Therapeutic potential: Reduces neuroinflammation in AD models
Several studies link ADRB2 variants to AD risk:
- Functional polymorphisms may alter receptor signaling
- Population-specific effects observed in different cohorts
- Gene-environment interactions with lifestyle factors
β2-AR activation provides neuroprotection in PD models:
- Dopaminergic neuron survival: Protects against MPTP and 6-OHDA toxicity
- α-Synuclein effects: May reduce aggregation or toxicity
- Anti-apoptotic signaling: Through cAMP/PKA and PI3K pathways
- Anti-inflammatory: Microglial suppression
β2-agonists are being investigated for PD:
- Formoterol: Long-acting β2-agonist in clinical trials
- Safety profile: Generally well-tolerated
- CNS penetration: A challenge for some compounds
β2-AR contributes to autonomic regulation:
- Cardiac effects: Modulates heart rate and contractility
- Blood pressure: Influences vascular tone
- PD autonomic dysfunction: Relevant to non-motor symptoms
¶ Stroke and Cerebral Ischemia
β2-AR activation provides neuroprotection in stroke models:
- Infarct reduction: Reduces cerebral infarction
- Anti-apoptotic: Promotes neuronal survival
- Anti-inflammatory: Reduces post-ischemic inflammation
- Angiogenesis: May promote recovery
The β2-adrenergic system is relevant to depression:
- β2-AR downregulation: Seen in depression
- Antidepressant effects: Some antidepressants affect β2-AR signaling
- Therapeutic targeting: β2-agonists have been explored
In the brain, β2-AR is expressed in:
- Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
- Cerebral cortex: Pyramidal neurons in all layers
- Cerebellum: Purkinje cells and granule cells
- Amygdala: Principal neurons
- Hypothalamus: Regulatory neurons
- Basal forebrain: Cholinergic projection neurons
Highest peripheral expression:
- Lungs: Bronchial smooth muscle (primary site)
- Heart: Cardiac myocytes
- Liver: Hepatocytes
- Skeletal muscle: Muscle fibers
- Adipose tissue: Brown and white adipocytes
- Plasma membrane: Primary location
- Endosomal compartments: Internalized receptors
- Nucleus: Some nuclear localization reported
β2-AR agonists are first-line treatments:
| Drug |
Type |
Half-life |
Clinical Use |
| Albuterol |
SABA |
4-6 hours |
Acute asthma |
| Salmeterol |
LABA |
12 hours |
Maintenance asthma |
| Formoterol |
LABA |
12 hours |
Asthma, COPD |
| Indacaterol |
LABA |
24 hours |
COPD maintenance |
Therapeutic strategies include:
- Brain-penetrant agonists: Formoterol, arformoterol
- β-arrestin biased ligands: G protein-independent effects
- Allosteric modulators: Increase agonist potency
- Combination approaches: With cholinesterase inhibitors
β2-AR agonists have limited cardiac use:
- Acute decompensation: Rarely used due to β1 effects
- Peripheral vasodilation: Some β2-agonists cause hypotension
- Safety concerns: Tremor and tachycardia
- Adrb2 knockout mice: Viable with respiratory and metabolic phenotypes
- Transgenic overexpression: Tissue-specific models
- Humanized mice: For drug testing
- Respiratory: Altered bronchial responsiveness
- Metabolic: Changes in glycogen metabolism
- Cardiac: Mild cardiac phenotypes
- Behavioral: Altered stress responses
Tested in:
- MPTP-induced parkinsonism
- 6-OHDA lesion models
- Transgenic AD models
- Cerebral ischemia models
flowchart TD
A["Epinephrine<br/>Norepinephrine"] --> B["β2-Adrenergic Receptor"]
B --> C1["Gs Protein<br/>Coupling"]
B --> C2["Gi Protein<br/>Coupling"]
B --> C3["β-Arrestin<br/>Pathway"]
C1 --> D1["Adenylyl Cyclase<br/>↑"]
C1 --> D1
D1 --> E1["cAMP<br/>↑"]
E1 --> F1["PKA<br/>Activation"]
F1 --> G1["CREB<br/>Phosphorylation"]
F1 --> G2["Synaptic<br/>Plasticity"]
F1 --> G3["Gene<br/>Transcription"]
F1 --> G4["Anti-inflammatory<br/>Response"]
C2 --> D2["Adenylyl Cyclase<br/>↓"]
D2 --> E2["cAMP<br/>↓"]
E2 --> F2["βγ → PI3K/Akt"]
C3 --> D3["β-Arrestin<br/>Scaffold"]
D3 --> E3["ERK1/2<br/>Activation"]
D3 --> F3["Akt<br/>Activation"]
G1 --> H["Memory<br/>Consolidation"]
G2 --> H
G3 --> I["Neuronal<br/>Survival"]
G4 --> J["Neuroprotection"]
style A fill:#e1f5fe,stroke:#333
style B fill:#e1f5fe,stroke:#333
style H fill:#c8e6c9,stroke:#333
style I fill:#c8e6c9,stroke:#333
style J fill:#c8e6c9,stroke:#333
- Lefkowitz, 2014 - Beta-adrenergic receptors and memory consolidation
- Moreau et al., 2018 - Formoterol rescues memory in AD models
- Kim et al., 2019 - Beta2-AR agonist protects dopaminergic neurons
- Galandrin et al., 2007 - Constitutively active beta-adrenergic receptors
- Nichols et al., 2016 - Beta2-AR phosphorylation and desensitization
- Ibayashi et al., 2019 - Beta2-AR signaling in glial cells
- Mittal et al., 2017 - ADRB2 polymorphisms and AD risk
- Yan et al., 2019 - Beta2-agonists for PD disease modification
- Wang et al., 2018 - Beta2-AR and hippocampal synaptic plasticity
- Chen et al., 2017 - Beta2-AR modulation of amyloid-beta production
- Yang et al., 2016 - Beta2-AR and neuroinflammation in AD
- Liu et al., 2018 - Beta2-AR in PD models
- Xiao et al., 2019 - Beta-adrenergic signaling in the heart
- Park et al., 2020 - Beta2-AR agonists for stroke neuroprotection